Last updated: September 25, 2026
Perindopril erbumine is a mature small-molecule ACE inhibitor with limited remaining exclusivity and low formulation complexity. The strongest commercial opportunities are low-cost generic tablets, differentiated fixed-dose combinations, lifecycle reformulations, and region-specific supply. Excipient selection should prioritize moisture control, chemical stability, content uniformity, dissolution performance, and robust tablet manufacture.
What is the commercial status of perindopril erbumine?
Perindopril erbumine is the tert-butylamine salt of perindopril, an orally administered prodrug converted in vivo to perindoprilat. The product was marketed in the United States as Aceon by Solvay Pharmaceuticals in 2 mg, 4 mg, and 8 mg tablet strengths. The FDA-approved indication was treatment of hypertension. [1]
| Attribute |
Perindopril erbumine |
| Active ingredient |
Perindopril erbumine |
| Pharmacologic class |
ACE inhibitor |
| Active metabolite |
Perindoprilat |
| Primary dosage form |
Immediate-release tablet |
| Historical U.S. brand |
Aceon |
| U.S. strengths |
2 mg, 4 mg, 8 mg |
| Regulatory pathway for generic |
ANDA, subject to applicable FDA requirements |
| Biologic status |
Not a biologic; biosimilar pathway does not apply |
| Main technical risks |
Moisture, hydrolysis, salt-form control, dissolution, blend uniformity |
| Main commercial risks |
Low pricing, established generic competition, limited U.S. branded demand |
The product competes with ramipril, enalapril, lisinopril, losartan and other antihypertensive therapies. Perindopril is more commercially established in Europe and other international markets than in the United States.
What patents protect perindopril erbumine?
The original compound and pharmaceutical composition patents for perindopril are expired or commercially exhausted in the principal markets. Perindopril erbumine is therefore a low-exclusivity generic opportunity rather than an originator-protected product.
The relevant U.S. patent position is summarized below.
| Patent category |
Current commercial position |
| Original perindopril compound patents |
Expired |
| Perindopril erbumine composition patents |
Expired or no longer commercially blocking |
| Core antihypertensive method-of-use patents |
Expired |
| Aceon formulation patents |
No material active Orange Book protection identified in the cited FDA materials |
| Pediatric exclusivity |
No current material exclusivity identified |
| Orphan-drug exclusivity |
Not applicable |
| Biosimilar exclusivity |
Not applicable |
The FDA Orange Book is the primary source for patents listed against approved small-molecule products. A current commercial program should verify the live Orange Book record and any applicable patent certifications before filing. [2]
How strong is the patent estate for perindopril erbumine?
The core patent estate is weak from a generic-entry perspective. Product protection is not the principal barrier. Any residual intellectual-property value is more likely to arise from:
- A novel solid form or polymorph
- A low-moisture formulation
- A modified-release dosage form
- A fixed-dose combination
- A manufacturing process with improved yield or impurity control
- A regional patent covering a specific formulation or combination
A standard immediate-release tablet containing conventional excipients is unlikely to create durable blocking protection unless it demonstrates a genuinely differentiated technical effect.
When does perindopril erbumine lose exclusivity?
Perindopril erbumine lost practical product exclusivity years ago. The original branded product was approved in the United States in 1999, and the core market is now governed by generic competition rather than originator exclusivity. [1]
| Exclusivity element |
Status |
| New chemical entity exclusivity |
Expired |
| Core composition protection |
Expired |
| Original method-of-use protection |
Expired |
| Formulation exclusivity |
No material current barrier identified |
| Generic entry |
Legally available, subject to ANDA approval and commercial supply |
What excipients are used in perindopril erbumine tablets?
Historical Aceon labeling identifies conventional tablet excipients, including lactose, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate. Excipients can vary by manufacturer and strength. [1]
A commercially practical formulation platform would normally consider the following excipient functions:
| Formulation function |
Candidate excipients |
Commercial rationale |
| Diluent |
Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate |
Controls tablet size, compressibility and cost |
| Binder |
Povidone, copovidone, pregelatinized starch |
Improves granule and tablet strength |
| Disintegrant |
Croscarmellose sodium, crospovidone, sodium starch glycolate |
Supports rapid immediate-release dissolution |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow and blend uniformity |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Reduces ejection force and tooling adhesion |
| Moisture-control excipient |
Low-moisture grades of lactose, mannitol or microcrystalline cellulose |
Reduces hydrolytic degradation risk |
| Film coating |
Hypromellose, polyethylene glycol, titanium dioxide or iron oxide where permitted |
Improves appearance, handling and light protection |
The formulation should not assume that a conventional ACE-inhibitor platform will provide equivalent stability. Perindopril is an ester-containing prodrug, and ester hydrolysis can generate degradation products under unfavorable moisture and temperature conditions. Salt form, water activity, packaging and manufacturing humidity therefore require early development attention.
What excipient strategy is best for perindopril erbumine?
A direct-compression formulation is the lowest-cost starting point when powder flow, compressibility and content uniformity are acceptable. A dry-granulation or roller-compaction process may be preferable when the active pharmaceutical ingredient has poor flow or when wet processing creates unacceptable degradation risk.
Recommended development sequence
- Screen the active ingredient for particle-size distribution, bulk density, hygroscopicity, polymorphism and salt-form consistency.
- Compare direct compression with dry granulation.
- Evaluate lactose, microcrystalline cellulose and mannitol as primary diluent systems.
- Screen croscarmellose sodium, crospovidone and sodium starch glycolate for disintegration.
- Compare magnesium stearate with sodium stearyl fumarate if lubrication affects dissolution.
- Conduct binary and ternary compatibility studies under accelerated conditions.
- Optimize moisture-barrier packaging before changing the active or salt form.
- Establish discriminatory dissolution methods across all strengths.
The preferred commercial formulation will normally be the simplest composition that meets assay, degradation, content uniformity, tablet strength, friability and dissolution targets.
Is lactose appropriate?
Lactose is commercially attractive because it is inexpensive, widely available and well understood. It may support robust tableting when combined with microcrystalline cellulose. Its suitability depends on the active-excipient compatibility profile, residual moisture and manufacturing conditions.
A lactose-containing formulation should be assessed for:
- Perindopril-related degradation under elevated humidity
- Reducing-sugar interactions
- Blend segregation
- Compression-force sensitivity
- Dissolution changes after storage
Mannitol can be considered where a lower-moisture diluent is preferred, although it can increase formulation cost and may require greater attention to compaction behavior.
Is microcrystalline cellulose appropriate?
Microcrystalline cellulose is a strong candidate for direct compression and dry granulation. It improves compactibility and can support rapid tablet disintegration. Excessive levels may produce soft, elastic compacts or affect dissolution through a high-fiber matrix.
A lactose-microcrystalline cellulose blend is commercially credible for low-dose perindopril erbumine, provided the process controls segregation. The active dose is small enough that blend uniformity can become more important than total tablet weight.
What formulation patents could create commercial value?
Patent value would most likely come from a formulation with a measurable technical advantage rather than from routine excipient substitution.
Moisture-stable formulations
A patent may be commercially relevant if it claims a defined excipient ratio, water activity, packaging system or impurity profile that materially improves shelf life. Generic claims such as "a tablet comprising perindopril and a pharmaceutically acceptable excipient" are unlikely to provide strong protection.
Potentially useful claim elements include:
- Specified residual-water limits
- Defined degradation-product thresholds
- A low-moisture excipient system
- A particular film-coating barrier
- Aluminum-aluminum blister packaging
- A stability profile demonstrated under ICH conditions
- A specific manufacturing sequence
Modified-release products
Perindopril erbumine is normally used as an immediate-release product. A modified-release formulation could create differentiated intellectual property, but the clinical and regulatory burden would rise sharply. The sponsor would need to demonstrate that the altered pharmacokinetic profile provides a meaningful therapeutic or adherence advantage.
Fixed-dose combinations
Fixed-dose combinations with amlodipine or indapamide offer more realistic lifecycle opportunities. Combination products can improve adherence and expand access in markets where perindopril-based regimens are established.
The principal risks are:
- Chemical incompatibility between active ingredients
- Different dose ratios across patient populations
- Dissolution interaction
- Additional bioequivalence requirements
- Combination-specific patent claims
- Regulatory requirements for each active ingredient
What is the FDA regulatory status of perindopril erbumine?
Perindopril erbumine is regulated as a conventional small-molecule drug. A generic tablet would generally proceed through the ANDA pathway if it matches the reference product in active ingredient, strength, dosage form, route and applicable bioequivalence criteria. FDA guidance for immediate-release solid oral dosage forms supports a risk-based approach to formulation, dissolution and scale-up. [3]
A formulation change may trigger:
- Comparative dissolution testing
- Stability studies
- Pharmaceutical equivalence assessment
- Bioequivalence studies, depending on the change
- Manufacturing-process validation
- Updated labeling or CMC documentation
The FDA Inactive Ingredient Database can support excipient precedent analysis, but prior use in another product does not eliminate the need to assess maximum daily exposure, route, dosage form and patient population. [4]
Are there Paragraph IV challenges or patent litigation?
Perindopril erbumine is a mature generic product, and no active, material U.S. patent dispute is identified in the cited FDA product materials. A new ANDA applicant would still need to make the applicable patent certifications and conduct a current litigation search before filing.
Because the core patents are no longer commercially central, a Paragraph IV strategy is less likely to be the main value driver than:
- First-to-file timing for any newly listed patent
- Manufacturing cost
- Reliable active-ingredient supply
- Product availability
- State and national tender access
- International registrations
No biosimilar litigation risk applies because perindopril erbumine is a synthetic small molecule, not a biologic.
What generic launch risks exist?
Generic launch risk is moderate operationally and low from a core patent perspective.
| Risk |
Impact |
Mitigation |
| Low product price |
High |
Use simple, scalable process and low-cost excipients |
| Small-dose blend variability |
High |
Validate blending, sampling and segregation controls |
| Hydrolytic degradation |
High |
Control humidity and use barrier packaging |
| API supply interruption |
High |
Qualify multiple suppliers and salt-form specifications |
| Dissolution failure |
Medium |
Optimize disintegrant and lubrication levels |
| Limited U.S. demand |
High |
Prioritize Europe, Asia and tender markets |
| Fixed-dose combination complexity |
Medium |
Separate combination feasibility from base-product launch |
| Formulation patent risk |
Low to medium |
Conduct jurisdiction-specific freedom-to-operate review |
Which companies and markets offer commercial opportunities?
Perindopril is commercially stronger in markets where physicians routinely prescribe ACE inhibitors and where perindopril-based combinations are established. Europe, parts of Asia, the Middle East and selected Latin American markets are more relevant than the U.S. branded market.
Potential commercial models include:
- Low-cost generic tablets
- Contract manufacturing for regional licensees
- Private-label supply
- Perindopril-amlodipine combinations
- Perindopril-indapamide combinations
- Multi-strength hospital and tender portfolios
- Moisture-stable products for hot and humid climates
The competitive landscape includes established generic manufacturers, regional pharmaceutical companies and contract development and manufacturing organizations. The active ingredient is not technically difficult to formulate, so manufacturing scale, regulatory execution and supply reliability are more important than proprietary excipient technology.
How does perindopril erbumine compare with other ACE inhibitors?
| Product |
Generic maturity |
Formulation complexity |
Commercial differentiation |
| Perindopril erbumine |
High |
Low to moderate |
Combination products and regional demand |
| Lisinopril |
Very high |
Low |
Lowest-cost volume market |
| Enalapril maleate |
Very high |
Low |
Broad global generic use |
| Ramipril |
High |
Low to moderate |
Cardiovascular outcome positioning |
| Benazepril |
High |
Low |
Regional and combination opportunities |
Perindopril has a prodrug structure and ester functionality that can create greater stability sensitivity than some simpler ACE inhibitors. That difference can support a technical formulation strategy, but not necessarily a high-margin product.
Key Takeaways
- Perindopril erbumine is a mature small-molecule generic opportunity with no meaningful core exclusivity barrier.
- The principal technical issue is control of moisture-related degradation and blend uniformity.
- Lactose, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate provide a credible low-cost formulation platform.
- Direct compression should be evaluated first, with dry granulation as the main alternative.
- Moisture-barrier packaging may deliver more commercial value than complex excipient innovation.
- Fixed-dose combinations with amlodipine or indapamide offer stronger lifecycle potential than a standard tablet.
- Biosimilar risk does not apply.
- Commercial returns will depend on manufacturing cost, API security, regional demand and regulatory execution.
FAQs
Can perindopril erbumine be formulated as an orally disintegrating tablet?
Yes, but the commercial rationale is limited unless the product demonstrates a meaningful adherence or swallowing benefit. ODT development would require tight control of taste, mechanical strength, disintegration time, moisture uptake and packaging.
Does perindopril erbumine require a special packaging system?
A moisture-protective package is commercially prudent. Aluminum-aluminum blisters or high-barrier bottles with an appropriate desiccant may be preferable to low-barrier packaging when stability data show sensitivity to humidity.
Can perindopril arginine replace perindopril erbumine in a generic product?
No. Perindopril arginine and perindopril erbumine are different salt forms. Substitution would require separate pharmaceutical-equivalence, bioequivalence and regulatory analysis.
Is a perindopril erbumine transdermal product commercially realistic?
It is technically possible but commercially unattractive. The conventional oral dose is well established, while transdermal development would face penetration, dose-delivery, adhesive and clinical-development barriers.
Which excipient offers the best opportunity for differentiated intellectual property?
No single excipient is likely to create strong protection. The strongest potential would come from a defined low-moisture formulation and packaging system tied to improved stability, impurity control and shelf life.
References
- U.S. Food and Drug Administration. (1999). Aceon (perindopril erbumine) tablets prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (1995). Immediate release solid oral dosage forms: Scale-up and post-approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation.
- U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
- International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products.
- International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development.
